Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Core Insights - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines aimed at correcting abnormal gene expression to treat serious diseases [1][3] - The company will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, highlighting its focus on oncology and the potential of its Gene Traffic Control platform [1][2] Company Overview - Foghorn Therapeutics is engaged in discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system [3] - The company utilizes its proprietary Gene Traffic Control platform to systematically study, identify, and validate potential drug targets [3] - Foghorn is developing multiple product candidates specifically in the oncology sector [3] Event Participation - Management will participate in a fireside chat on December 4, 2025, at 9:10 a.m. EST, with a webcast available for 30 days [2][4] - The company will also engage in one-on-one meetings during the conference [4]